Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — Investor Presentation (August 2025)
39 slides from Fate Therapeutics's investor presentation, August 2025
Slide 1: Corporate Presentation
TRANSFORMING THE LIVES OF PATIENTS WITH AUTOIMMUNE DISEASES AND CANCER TM Making Cell Therapies Accessible to All Corporate Presentation August 2025 © 2025 Fate Therapeutics. All rights reserved. -1-
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: Uniting the transformational power of cell therapy with unencumbered access
“Uniting the transformational power of cell therapy with unencumbered access” - Bob Valamehr, President & CEO Making Cell Therapy Accessible to All -3-
Slide 4: Resetting the Paradigm - Not just the Patient
Resetting the Paradigm - Not just the Patient Pioneering the development of truly accessible cell therapies - available on demand - anywhere Unique Living Drug with Renewable Manufacturing Process Novel Therapy Paradigm Broad Disease Targeting Delivering On-Demand Cell Therapies Single-Step Multiple
Slide 5: A Differentiated & Renewable Cell Manufacturing Process
A Differentiated & Renewable Cell Manufacturing Process Fate’s platform uniquely delivers cell therapies on-demand to all patients in need Autologous CAR T Cell Allogeneic CAR T Cell Accessible CAR T Cell • Profound efficacy in difficult-to- • Potential for profound efficacy in • Potential for profo
Slide 6: Immune Modulation Therapeutic Landscape
Immune Modulation Therapeutic Landscape Fate’s preprogrammed CAR T cells deliver potency of a living drug with uniformity of traditional biologics In Vivo T Cell Reprogramming Preprogrammed T cells Protein Engagers Viral Synthetic mAb T cell engager LV AAV NC LNP Limited disease reach through reduce
Slide 7: Unique Platform for Delivery of Off-the-Shelf Cellular Therapies
Unique Platform for Delivery of Off-the-Shelf Cellular Therapies Mass produced, multiplexed-engineered cell products for on-demand patient treatment Induced Single product Clonal Master Cell Stored Drug Treat thousands of pluripotent stem candidate clone Bank (MCB) Inventory patients on-demand cell
Slide 8: Mass Production of Cell Therapy Drug Products
Mass Production of Cell Therapy Drug Products Advanced manufacturing capabilities to provide clinical and early commercial supply State of the Art GMP facility (San Diego, CA, USA) • 40,000+ ft2 Fate cGMP manufacturing facility co-located with corporate headquarters • End-to-end capabilities and con
Slide 9: Addressing Diseases with Significant Unmet Clinical Need
Addressing Diseases with Significant Unmet Clinical Need Reaching patients in their communities with an off-the-shelf treatment without lympho-conditioning chemotherapy Autoimmune Disease Oncology Antineutrophilic Idiopathic Systemic Lupus Systemic cytoplasmic anti- Inflammatory HER2+ Pan Tumor Eryt
Slide 10: First-in-Class Product Pipeline
First-in-Class Product Pipeline Multiplexed-engineered, iPSC-derived product candidates Program CAR/Antigen Target Indication Research Preclinical Phase 1 (NCT#) Partner Autoimmunity Systemic Lupus Erythematosus (SLE) FT819-102 Systemic Sclerosis (SSc) FT819-102 FT819 NCT06308978 CD19 Enrolling (RMA
Slide 11: FT819 Program
FT819 Program CD19 Targeting CAR T-Cell Product Candidate Making Cell Therapy Accessible to All - 11 -
Slide 12: Systemic Lupus Erythematosus (SLE): A Disease of Significant Unmet Need
Systemic Lupus Erythematosus (SLE): A Disease of Significant Unmet Need Chronic disease burden, multi-organ involvement and increased morbidity & mortality High disease burden, disability & organ damage • Typical patient is a women of childbearing age presenting with fatigue, joint pain, rash and sy
Slide 13: FT819: Off-the-Shelf anti-CD19 CAR T-Cell Product Candidate
FT819: Off-the-Shelf anti-CD19 CAR T-Cell Product Candidate Safe and effective targeting of CD19+ B cells with broad patient accessibility True Off-the-Shelf CAR T-Cell Drug Product Derived from a defined clonal MCB incorporating unique functional elements to balance safety and efficacy: • 1XX CAR19
Slide 14: FT819 Provides Rapid and Dose Dependent B Cell Elimination
FT819 Provides Rapid and Dose Dependent B Cell Elimination Relative CD19 CAR T cell activity against SLE patient derived PBMCs show FT819 to be highly potent CAR T-cell Product Uniformity 100 FT819 demonstrates superior Manufacturing & Engineering Process Influences Product Uniformity and Potency %
Slide 15: FT819-102: Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases
FT819-102: Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases1 Uniquely administered with fludarabine-free conditioning or maintenance therapy in the absence of chemotherapy conditioning Clinical Trial NCT063089782 Highly-Differentiated Therapeutic Approach Available on-demand with: • No
Slide 16: FT819-102: SLE patient disease characteristics
FT819-102: Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases1 SLE patient disease characteristics Patient Characteristics Regimen A Regimen B Patient # A1-DL1 A2-DL1 A3-DL1 A1-DL2 B1-DL1 Age, Gender 28 F 22 F 29 F 28 F 23 F BILAG domain for MSK, Renal Renal Renal Cardiorespiratory inclus
Slide 17: FT819-102: Preliminary clinical safety data
FT819-102: Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases1 Preliminary clinical safety data No high-grade CRS, No ICANS, and No DLTs observed Safety data in line with FT819-101 in B cell lymphoma (NCT04629729) Selected Adverse Events, Highest Grade Reported Regimen A Regimen B Patient
Slide 18: FT819-102 Activity in SLE: DORIS Remission >1 Year Indicates Durable Response
FT819-102 Activity in SLE: DORIS Remission >1 Year Indicates Durable Response Patient 1 SLE case (A1-DL1) Remission in SLE without use of steroids Sustained improvement in overall patient status 3 Maintained on HCQ 20 ✓ No leukapheresis No steroids since 3M visit PGA Score 2 ✓ Fludarabine-free lymph
Slide 19: FT819-102 Durability of Remission is Supported by B-cell Immunological Reset
FT819-102 Durability of Remission is Supported by B-cell Immunological Reset Patient 1 SLE case (A1-DL1) Effective B cell depletion & repopulation to normal levels* Reconstituting B cells are predominantly naïve, minimal switched memory, and low plasmablasts indicative of immune reset Total Peripher
Slide 20: FT819-102 Collective Reduction in Disease with Fludarabine-Free Conditioning
FT819-102 Collective Reduction in Disease with Fludarabine-Free Conditioning Patients 1 - 4 in Regimen A (Cyclophosphamide or Bendamustine monotherapy lympho-conditioning) Persistent improvement in Renal responses achieved Improved disease activity across all patients overall patient status (n4) in
Slide 21: FT819-102: Remission in SLE Achieved Without Lympho-Conditioning
FT819-102: Remission in SLE Achieved Without Lympho-Conditioning First patient (B1-DL1) in Regimen B (FT819 as add-on to maintenance therapy) Remission in SLE without lympho-conditioning Persistent improvement Preservation of baseline in overall patient status immune cells Maintained on MMF, prednis
Slide 22: FT819-102 Summary and Next Steps
FT819-102 Summary and Next Steps ➢ FT819 provides a true off-the-shelf CAR T cell therapeutic option that overcomes many of the challenges seen in autologous and allogenic cellular therapies ➢ Preliminary clinical data suggests FT819 can support durable clinical activity with less intensive conditio
Slide 23: FT825 Program
FT825 Program HER2 Targeting CAR T-Cell Product Candidate Making Cell Therapy Accessible to All - 23 -
Slide 24: Seven-Point Edited HER2-Directed CAR T-Cell Therapy Designed for Enhanced Solid Tumor Efficacy
Seven-Point Edited HER2-Directed CAR T-Cell Therapy Designed for Enhanced Solid Tumor Efficacy FT825/ONO-8250: Off-the-shelf anti-HER2 CAR T-cell product candidate Overcoming the Challenges in Solid Tumors • TCR Null: Complete bi-allelic disruption of TRAC ablates TCR expression and eliminates the p
Slide 25: Novel Cancer-Specific CAR Binder Limits Off Tumor Toxicity
Novel Cancer-Specific CAR Binder Limits Off Tumor Toxicity FT825/ONO-8250 designed for preferential and multi-antigen targeting • Novel binder (H2CasMab-2) preferentially targets HER2 expressed on tumor HER2+++ HER2+ Tumor Tissue Normal Tissue cells with limited on-target off-tumor toxicity Hercepti
Slide 26: FT825/ONO-8250-101: A Phase 1 Study of FT825 in Advanced Solid Tumor
FT825/ONO-8250-101: A Phase 1 Study of FT825 in Advanced Solid Tumor Phase 1 Study: FT825/Ono0825 with/without monoclonal antibody combination (NCT06241456) Clinical Trial NCT062414561 • HER2+ Breast, Gastric, GEJ, Early Clinical Observations Regimen A: HER2Mut NSCLC FT825 Monotherapy • HER2+ saliva
Slide 27: Next Generation CAR T Cells
NEXT GENERATION CAR T CELLS FT836 Program FT839 Program MICA/B Targeting CD19/CD38 Targeting CAR T-Cell Product Candidate CAR T-Cell Product Candidate Making Cell Therapy Accessible to All - 27 -
Slide 28: Engineering a Portfolio of Attributes to Unlock Multi-Disease Therapy Potential
Engineering a Portfolio of Attributes to Unlock Multi-Disease Therapy Potential Integrating modular attribute cell systems to operate & synergize with the patients’ immune system Overcoming Multiple Tumor Challenges Broad Elimination of Pathological Across Diverse Tumors Indications Immune Cell Subs
Slide 29: Sword & Shield Technology Shields from Rejection & Drives Persistence
Sword & ShieldTM Technology Shields from Rejection & Drives Persistence Best-in-class allo-immune evasion system to enhance persistence & eliminate the need for lympho-conditioning Combination with HLA-I & HLA-II HLA-I & HLA-II HLA-I & HLA-II Sword & ShieldTM Strategy Intense CCT Knockout Knockout +
Slide 30: Targeting MICA/B Inhibits Tumor Resistance & Unlocks Pan-Tumor Potential
Targeting MICA/B Inhibits Tumor Resistance & Unlocks Pan-Tumor Potential FT836: Off-the-shelf anti-MICA/B CAR T-cell product candidate Novel recognition of MICA/B α3 MICA/B shedding is a common immune MICA/B is widely expressed across multiple cancer indications5 domain unlocks pan-tumor targeting1,
Slide 31: CD19/CD38 Co-Targeting Delivers Potent, Multi-Compartment Immune Ablation
CD19/CD38 Co-Targeting Delivers Potent, Multi-Compartment Immune Ablation FT839: Off-the-shelf anti-CD19/CD38 dual CAR T-Cell product candidate B cell lineage and activated immune cell state antigen targeting FT839 eliminates B cells & allo-reactive immune cells3 Data source2 High Target Biology: HS
Slide 32: Upcoming Milestones for NxG CAR T Cell Candidates
Upcoming Milestones for NxG CAR T Cell Candidates Phase 1 clinical evaluation ready in 2025 FT836 Product Candidate FT839 Product Candidate Attribute Systems: ➢ IND cleared July 2025 Attribute Systems: ➢ Anticipated IND filing by YE 2025 ➢ Targeting - ➢ Planning for Phase 1 Trials: ➢ Targeting - ➢ P
Slide 33: FT522 Program
FT522 Program CD-19 CAR NK Cell Product Candidate Making Cell Therapy Accessible to All - 33 -
Slide 34: Multi-Antigen Targeting CAR NK Cell Armed with ADR to Avoid the Need for Conditioning Chemotherapy
Multi-Antigen Targeting CAR NK Cell Armed with ADR to Avoid the Need for Conditioning Chemotherapy FT522: Off-the-shelf anti-CD19 CAR NK cell product candidate True Off-the-Shelf Next Gen CAR NK cell ADR armed NK Cells Uniquely Able to Drug Product Proliferate and Persist • 1XX CAR19: Novel CAR with
Slide 35: FT522-101 Program for B-cell Lymphoma
FT522-101 Program for B-cell Lymphoma Phase 1 Clinical Trial Design Clinical Trial NCT059503341 Proof-of-concept for Therapeutic Approach • FT522 demonstrated activity and tolerability in B cell lymphoma • Pharmacokinetics suggest improved long term FT522 persistence without chemo-conditioning, with
Slide 36: FT522 Phase 1 Basket Study in Autoimmunity
FT522 Phase 1 Basket Study in Autoimmunity IND cleared: Clinical development strategic planning ongoing No Conditioning; Multiple Indications; Induction and Maintenance Regimens Basket Trial Design AAV = Antineutrophilic cytoplasmic antibody-associated vasculitis IIM = Idiopathic inflammatory myosit
Slide 37: Near Term Milestones
Near Term Milestones Making Cell Therapy Accessible to All - 37 -
Slide 38: 2025 Corporate Highlights
2025 Corporate Highlights Competitively positioned to accelerate next stage of the company Near Term (within 6-9 months) Anticipated Milestones: • Removal of hospitalization requirement for FT819 • Alignment with FDA on FT819 pivotal trial design in SLE • FT819 study site expansion, including into E
Slide 39: Transforming the Lives of Patients with Autoimmune Diseases and Cancer
TRANSFORMING THE LIVES OF PATIENTS WITH AUTOIMMUNE DISEASES AND CANCER TM Making Cell Therapies Accessible to All July 2025 © 2025 Fate Therapeutics. All rights reserved. www.fatetherapeutics.com - 39 -
Fate Therapeutics — Investor Presentation (August 2025) on 6ix